A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
- Conditions
- Interventions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT05849298
- Locations
- 🇺🇸
Urology Clinic of North Texas, Dallas, Texas, United States
🇺🇸Univ of Texas Southwest Med Center Cardiovasc And Thoracic Surg, Dallas, Texas, United States
🇺🇸Urology Cancer Center PC, Omaha, Nebraska, United States
Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib
- Conditions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2023-05-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 543
- Registration Number
- NCT05848219
- Locations
- 🇺🇸
Novartis Investigational Site, East Hanover, New Jersey, United States
Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes in Chronic Heart Failure Patients in the U.S.
- Conditions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2023-05-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 251831
- Registration Number
- NCT05848206
- Locations
- 🇺🇸
IQVIA, Durham, North Carolina, United States
Efficacy, Safety and Tolerability of KLU156 in Adults and Children ≥ 5 kg Body Weight With Uncomplicated P. Falciparum Malaria
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1500
- Registration Number
- NCT05842954
- Locations
- 🇳🇪
Novartis Investigative Site, Niamey, Niger
LUTATHERA Injection General Use Result Survey
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 347
- Registration Number
- NCT05844332
- Locations
- 🇯🇵
Novartis Investigative Site, Yamagata, Japan
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 327
- Registration Number
- NCT05838768
- Locations
- 🇺🇸
University of California LA, Los Angeles, California, United States
🇬🇧Novartis Investigative Site, Oxford, United Kingdom
🇺🇸Columbia University Medical Ctr, New York, New York, United States
A Retrospective Study to Evaluate the Early Real-world Evidence of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) in India
- Conditions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 63
- Registration Number
- NCT05834075
- Locations
- 🇮🇳
Disha Eye Hospital, Kolkata, India
🇮🇳Dr. Milan's Retina Care Center, Rajkot, India
🇮🇳Susrut Eye Foundation and Research Center, Kolkata, India
Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers
- Conditions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 297
- Registration Number
- NCT05833022
- Locations
- 🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸Cristiana Care, Wilmington, Delaware, United States
🇺🇸All Children's Hospital, Saint Petersburg, Florida, United States
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 3100
- Registration Number
- NCT05827081
- Locations
- 🇦🇺
Novartis Investigative Site, Gateshead, New South Wales, Australia
Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo
- Conditions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 368
- Registration Number
- NCT05826028
- Locations
- 🇦🇺
Novartis Investigational Site, St Leonards, New South Wales, Australia